Patients will receiv e at 3 biweekly vaccines as long as clinically stable. Studies in patients receiving myeloablative and NMA chemotherapy have shown that T cell function normalizes (without intervening immunotherapy) between 6- 12 months in most patients. Patients will be followed bi-monthly (+/ - one month) for first year post immunotherapy, then every 3 months (+/ - one month) until death due to any cause. As part of standard care for these patients, upon tumor progression, participants may undergo stereotactic biopsy or r esection. As this is not a research procedure consent will be obtained separately. However, if tissue is obtained, it will be used to confirm tumor progression histologically and to assess immunologic cell infiltration and antigenic profile changes from t he initially resected tumor specimen used in vaccine preparation.